Orion Portfolio Solutions LLC Decreases Stake in AngioDynamics, Inc. (NASDAQ:ANGO)

Orion Portfolio Solutions LLC trimmed its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 3.0% during the third quarter, Holdings Channel reports. The firm owned 167,514 shares of the medical instruments supplier’s stock after selling 5,155 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in AngioDynamics were worth $1,303,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its position in AngioDynamics by 110.4% during the third quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock worth $1,240,000 after purchasing an additional 83,622 shares in the last quarter. First Eagle Investment Management LLC purchased a new stake in AngioDynamics during the second quarter worth $1,321,000. Systematic Financial Management LP boosted its position in AngioDynamics by 8.4% during the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock worth $12,763,000 after purchasing an additional 162,972 shares in the last quarter. CWM LLC boosted its position in AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 8,832 shares in the last quarter. Finally, Royce & Associates LP boosted its position in AngioDynamics by 10.8% during the third quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier’s stock worth $7,672,000 after purchasing an additional 96,138 shares in the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of AngioDynamics stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the transaction, the chief executive officer now owns 681,582 shares of the company’s stock, valued at $4,109,939.46. This represents a 3.02 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders have acquired 22,568 shares of company stock worth $135,847. 5.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on ANGO. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research report on Tuesday, December 10th. Canaccord Genuity Group cut their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday, October 4th.

AngioDynamics Stock Down 2.0 %

NASDAQ ANGO opened at $9.00 on Friday. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $9.42. The stock has a market cap of $365.71 million, a price-to-earnings ratio of -1.48 and a beta of 0.68. The business has a fifty day moving average of $7.02 and a 200-day moving average of $6.95.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. During the same period in the prior year, the firm posted ($0.12) earnings per share. The business’s quarterly revenue was down 14.2% compared to the same quarter last year. As a group, analysts anticipate that AngioDynamics, Inc. will post -0.41 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.